<DOC>
	<DOCNO>NCT00989872</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , ascend single dose safety , tolerability , pharmacokinetic study orally administer EDP-322 . This study conduct single site . EDP-322 benefit risk profile support test target patient population .</brief_summary>
	<brief_title>Safety Pharmacokinetics Ascending Single Oral Doses EDP-322 Nonfasting Fasting Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<criteria>Healthy adult male female [ documentation exist surgically sterilize ] . Were good general health determine medical history , physical exam clinical laboratory test , without evidence clinically significant abnormality , opinion Investigator Medical Monitor . The rest 12lead ECG obtain Screening show clinically significant abnormality QTc ( Bazett 's correction ) &lt; 450 msec . Weight le 132 pound ( 60kg ) BMI 1832 kg/m3 , inclusive . Subject read , understood , sign write informed consent form . History chronic recurrent renal , hepatic , pulmonary , allergic , cardiovascular , gastrointestinal , endocrine , central nervous system , hematologic metabolic disease , immunologic , emotional and/or psychiatric disturbance . History gastric surgery , vagotomy , bowel resection , surgical procedure might interfere gastrointestinal motility , pH , absorption . Any abnormal screening clinical lab test result ... Medication Related exclusion ... Lifestyle relate ...</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Macrolides</keyword>
	<keyword>Antibiotics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>MRSA/SSTI</keyword>
</DOC>